Randomized trial of vitamin D versus placebo supplementation on markers of systemic inflammation in hypertensive patients.
Aged
Austria
Biomarkers
/ blood
Cholecalciferol
/ adverse effects
Dietary Supplements
/ adverse effects
Double-Blind Method
Female
Humans
Hypertension
/ blood
Inflammation Mediators
/ blood
Male
Middle Aged
Time Factors
Treatment Outcome
Vitamin D
/ analogs & derivatives
Vitamin D Deficiency
/ blood
Vitamins
/ adverse effects
Hypertension
Inflammation
Randomized controlled trial
Supplementation
Vitamin D
Journal
Nutrition, metabolism, and cardiovascular diseases : NMCD
ISSN: 1590-3729
Titre abrégé: Nutr Metab Cardiovasc Dis
Pays: Netherlands
ID NLM: 9111474
Informations de publication
Date de publication:
28 10 2021
28 10 2021
Historique:
received:
21
06
2021
revised:
21
07
2021
accepted:
28
07
2021
pubmed:
12
10
2021
medline:
23
11
2021
entrez:
11
10
2021
Statut:
ppublish
Résumé
Animal and cell models indicated that vitamin D modulates inflammatory activity, which is considered relevant in the pathogenesis of arterial hypertension and cardiovascular diseases. We therefore aimed to investigate the effect of vitamin D supplementation on systemic markers of inflammation in a cohort of hypertensive patients. The Styrian Vitamin D Hypertension Trial is a single-centre, double-blind, placebo-controlled study conducted from 2011 to 2014 in Austria. We enrolled 200 study participants with arterial hypertension and 25-hydroxy-vitamin-D (25(OH)D) concentration below 30 ng/mL. Study participants were randomized to receive either 2800 IU of vitamin D Vitamin D ClinicalTrials.gov Identifier: NCT02136771; EudraCT No. 2009-018,125-70. Start Date: 2011-04-06.
Sections du résumé
BACKGROUND AND AIMS
Animal and cell models indicated that vitamin D modulates inflammatory activity, which is considered relevant in the pathogenesis of arterial hypertension and cardiovascular diseases. We therefore aimed to investigate the effect of vitamin D supplementation on systemic markers of inflammation in a cohort of hypertensive patients.
METHODS AND RESULTS
The Styrian Vitamin D Hypertension Trial is a single-centre, double-blind, placebo-controlled study conducted from 2011 to 2014 in Austria. We enrolled 200 study participants with arterial hypertension and 25-hydroxy-vitamin-D (25(OH)D) concentration below 30 ng/mL. Study participants were randomized to receive either 2800 IU of vitamin D
CONCLUSION
Vitamin D
REGISTRATION
ClinicalTrials.gov Identifier: NCT02136771; EudraCT No. 2009-018,125-70. Start Date: 2011-04-06.
Identifiants
pubmed: 34629245
pii: S0939-4753(21)00349-5
doi: 10.1016/j.numecd.2021.07.028
pii:
doi:
Substances chimiques
Biomarkers
0
Inflammation Mediators
0
Vitamins
0
Vitamin D
1406-16-2
Cholecalciferol
1C6V77QF41
25-hydroxyvitamin D
A288AR3C9H
Banques de données
ClinicalTrials.gov
['NCT02136771']
EudraCT
['2009-018,125-70']
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
3202-3209Informations de copyright
Copyright © 2021. Published by Elsevier B.V.
Déclaration de conflit d'intérêts
Declaration of competing interest The authors have nothing to disclose.